F-10POS: Oncolytics Biotech Deregisters Unsold Securities
Post-Effective Amendment to Registration Statement
Oncolytics Biotech Inc. has filed a post-effective amendment to deregister unsold securities from multiple previous F-10 registration statements.
Summary
- Oncolytics Biotech Inc. is filing a post-effective amendment to its Form F-10 registration statements.
- The purpose of this filing is to withdraw and deregister any unsold securities that were previously registered under several prior registration statements dating back to 2007.
- These registration statements covered various types of securities including units, common shares, subscription receipts, warrants, and debt securities.
- The amendment is effective on April 16, 2026, at 4:30 p.m. Eastern time.
- The company certifies that it meets all requirements for filing on Form F-10.
Sentiment
Score: 3
Explanation: StockSavvy.ai views this as a neutral filing, as it is an administrative action to deregister unsold securities and does not reflect current operational performance or future strategic initiatives.
Future Outlook
This filing does not contain forward-looking statements or guidance; it pertains to the deregistration of previously registered but unsold securities.
Industry Context
StockSavvy.ai notes that this filing is a procedural administrative action by Oncolytics Biotech to clean up its historical SEC filings by removing registration statements for securities that were never issued or sold. This is a common practice for companies that have completed offerings or have had registration statements expire without full utilization.
Stakeholder Impact
- Shareholders: No direct impact as this filing concerns securities that were not sold and therefore do not represent outstanding shares or obligations.
Next Steps
- The deregistration of unsold securities will be effective on April 16, 2026.
Key Dates
| Date | Description |
|---|---|
| February 5, 2007 | Initial filing date for Registration Statement No. 333-140460. |
| February 8, 2007 | Initial filing date for Registration Statement No. 333-140529. |
| June 6, 2008 | Initial filing date for Registration Statement No. 333-151513. |
| June 2, 2010 | Initial filing date for Registration Statement No. 333-167250. |
| June 21, 2012 | Initial filing date for Registration Statement No. 333-182260. |
| July 25, 2014 | Initial filing date for Registration Statement No. 333-197633. |
| April 25, 2018 | Initial filing date for Registration Statement No. 333-224432. |
| June 8, 2020 | Initial filing date for Registration Statement No. 333-239025. |
| June 10, 2022 | Initial filing date for Registration Statement No. 333-265510. |
| July 25, 2024 | Initial filing date for Registration Statement No. 333-281009. |
| April 8, 2026 | Date of filing of the post-effective amendment. |
| April 16, 2026 | Effective date of the post-effective amendment. |
Keywords
Oncolytics Biotech, SEC Filing, Form F-10, Registration Statement, Deregistration, Securities, Common Shares, Units, Warrants, Debt Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.